Market Overview

UPDATE: Goldman Sachs Downgrades Diebold to Sell on Relative Valuation, Growth Risk

Related DBD
Diebold Names Signorello To Lead North America Sales
What Is A High Risk Market?

Goldman Sachs downgraded Diebold (NYSE: DBD) from Neutral to Sell and lowered the price target from $29.00 to $27.00.

Goldman Sachs commented, "On a sector relative basis, we downgrade DBD to Sell from Neutral as we are now more cautious on (1) the company's core ATM demand backdrop as banks focus on controlling expenses in a tough environment; (2) potential share losses in the US regional and Brazil ATM market to NCR where its order growth has shown relative strength; and (3) potential pricing risk from a shift in orders to larger banks."

Diebold closed at $30.77 on Tuesday.

Latest Ratings for DBD

DateFirmActionFromTo
Nov 2014Imperial CapitalMaintainsIn-line
Mar 2014Compass PointTerminatesSell
Feb 2014Imperial CapitalMaintainsIn-line

View More Analyst Ratings for DBD
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Downgrades Intraday Update Analyst Ratings

 

Related Articles (DBD)

Around the Web, We're Loving...

Get Benzinga's Newsletters